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the relevant clinical criteria. Individual Cancer Drug Fund requests (ICDFRs) can also 
be made for patients outside of routine cohort CDF criteria for rare diseases or, in 
cases where a decision has been made not to fund a cohort, for patients for whom 
clinical exceptionality from this cohort can be demonstrated. ICDFRs are screened to 
ensure that the request is appropriate and are then appraised by one of four regional 
CDF panels. This research aimed to evaluate whether access to oncologics through 
ICDFRs varies by region. Methods: ICDFR outcomes data (April 2013–March 2014) 
was extracted from the NHS website and stratified by NHS estimates of the resident 
population by region. All statistical analyses were performed using a Chi-squared 
test. Results: 1029 ICDFR applications were received for consideration (London, 
301; East and Midlands, 231; North England, 181; South England, 316), 46% of which 
were deemed ineligible by screening, significantly varying by region (p< 0.0001, 
range 22% (North England) to 67% (East and Midlands)). 50% of screened ICDFRs 
were approved, which varied substantially by region (p< 0.0001, range 37% (East and 
Midlands) to 72% (South England)). Overall, around 5.5 ICDFRs were accepted per 
million patients across England, however, between regions this ratio varied over 
six-fold (range 1.9 (East and Midlands) to 12.0 (South England)). ConClusions: The 
notable variations in ICDFR screening, acceptance, and population level approval 
rates, which are larger than what we may expect based on regional variations in case 
mix, suggest that regional areas must further collaborate to ensure that patients 
have equitable access to the Cancer Drugs Fund.
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iNCremeNTal CoST eFFeCTiveNeSS raTio oN FUNDiNg DeCiSioNS
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objeCtives: Oncology drugs in England rejected or not yet assessed by the National 
Institute for Health and Care Excellence (NICE) can seek funding through the Cancer 
Drug Fund (CDF). Each drug is given a score via the national CDF Prioritisation Tool 
which is a clinically-led process where cost-effectiveness is considered only as a 
tie-breaker. The objective of this research was to determine which score secures CDF 
approval and how the decision is related to the Incremental Cost Effectiveness Ratio 
(ICER). Methods: CDF drug reports (including the scores) published from April 
2013 until March 2014 were analysed and mapped to the national May CDF list. Each 
score comprises of a number indicating the clinical profile of the drug and the letter 
(A-D, U) representing the strength of evidence. The ICER per indication was sourced 
from NICE assessments and the relationship to the CDF list was analysed. Results: 
A review of 56 CDF reports showed that generally, drugs with scores below 1B (posi-
tive clinical profile, one Phase III published study) were not granted CDF funding. 
Positive decisions were made for 19 indications with scores ranging from 1B to 8B. 
The most common reasons for not approving drugs with a score of ≥ 1B were the 
trial not representing the NHS England population; lack of clinical effectiveness or 
questionable wider clinical support. The ICERs does not appear to have an influence 
on the CDF decision as ICERs for both CDF and non-CDF drugs ranged from £30,000 
to £150,000. ConClusions: The result of this research confirms that the clinical 
profile and the level of evidence are the most important factors for the CDF inclusion 
while cost-effectiveness is not a standard part of the decision-making process. The 
findings can also support manufacturers in estimating the likely outcome of the 
CDF application based on the pre-calculated score.
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objeCtives: The Russian pharmaceutical market is one of the fastest growing in the 
world. Its value is predicted to rise from $24 billion in 2013 to $75 billion by 2020(1). 
For industry the market opportunity is compelling, however market access across 
this vast region is complex and challenging, specifically for high-cost products. This 
research was conducted to have a closer look at the Russian pharmaceutical pricing 
and reimbursement model, and further explore access barriers. Methods: The 
research was conducted through in-depth secondary research and interviews with 
stakeholders in Russia including members of the Russian ministry of health, Federal 
health insurance fund, and regional/municipal health authorities. Results: At the 
federal level, the Ministry of Health and Social Development (MoHSD) develops 
strategy, policy and budgets in health care. The MoHSD has developed an Essential 
Drugs List (EDL) to ensure that drugs are made available at a harmonized price 
across Russia. However being listed on the EDL does not ensure reimbursement. In 
Russia, regional health authorities function as independent units. Drug provision 
and systems of reimbursement are usually developed at a regional level. However, 
each of the 82 Russian regions also has fundamentally different demographic and 
economic conditions, creating unique requirements and subsequent disparity in 
health care delivery and funding across the regions. It is critical for manufacturers 
to get their product listed in individual regional formularies, which will be used 
as the foundation for the reimbursement systems as they are rolled out in the 
future. ConClusions: The Russian market is vast, fast growing and clearly offers 
massive opportunities for pharmaceutical companies. However, this is a complex 
market, with a considerable regional variation in decision making. Industry will 
have to invest in gaining regional insight to determine priority regions and justify 
market access plans according to the dynamics of a specific region.
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performed to assess evolution of HRU and medical costs over time. Similar analysis 
was conducted for Medicare-eligible patients. Results: Of the 3,940 commercially-
insured and 1,658 Medicare-eligible individuals with NETs, 63.0% (n= 2,484) and 
67.0% (n= 1,111) were untreated, respectively. Among untreated commercially-
insured individuals with NETs, carcinoid syndrome (20.9%), nausea/vomiting (14.2%) 
and liver metastasis (11.6%) were the most prevalent symptoms/co-morbidities in 
the 12-month post-index period; 37.7 % had hospitalization admissions and 31.4% 
had emergency department (ED) visits, and the mean annual number of physician 
office visits was 18.7. The total monthly medical cost increased from $3,028 in the 
pre-index period to $4,159 in the post-index period. Among untreated Medicare-
eligible individuals with NETs, carcinoid syndrome (14.3%), nausea/vomiting (12.5%) 
and liver metastasis (11.9%) were the most prevalent symptoms/co-morbidities in 
the 12-month post-index period; 42.2 % had hospitalization admissions and 35.0% 
had ED visits, and the mean annual number of physician office visits was 25.5. The 
total monthly medical cost increased from $2,787 in the pre-index period to $3,788 
in the post-index period. ConClusions: Economic burden of untreated individuals 
with NETs is not negligible in the health care system. Future research should assess 
reasons for non-treatment, the impact of non-treatment on quality of life, and the 
benefit to cover this population with medical unmet need.
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objeCtives: Two vaccines protecting against human papillomavirus (HPV) infec-
tions are available in Bangladesh for the protection of girls against cervical can-
cer. These vaccines require cold chain storage and transportation to ensure their 
maximal efficacy. This storage may represent a large investment depending on 
the cold chain volume (CCV) needed. The objective of this study was to estimate 
and compare the total CCV needed for the vaccination of a single cohort of girls in 
Bangladesh accounting for the difference in packaging for each vaccine. Methods: 
The total CCV was estimated by multiplying the annual size of the cohort to be 
vaccinated by the CCV per dose and the number of doses needed per vaccination 
schedule. Additionally, a buffer factor of 10% as well as a wastage factor (5% for a 
1-dose-vial and 10% for a 2-dose-vial) were also accounted for as an assumption. 
Two vaccines were considered: the AS04-adjuvanted HPV-16/18 vaccine (AS04v) 
(2-dose-vial) and the HPV-6/11/16/18 vaccine (6/11/16/18V) (1-dose-vial). Dosing 
scheme (2-dose(2D) for AS04v, 3-dose(3D) for 6/11/16/18V) was according to label 
in Bangladesh. Alternative 2D for 6/11/16/18V recommended by World Health 
Organization (WHO) was also used. Their respective CCV per dose were obtained 
from the WHO Immunization Standards. A cohort size of N= 1,591,697 of girls aged 
10 eligible for vaccination was calculated from HPVCenter data. Results: CCV for 
AS04v is 4.8cm³ per dose for a 2-dose-vial and for 6/11/16/18V 15 cm³ per dose for 
a 1-dose-vial. To vaccinate a single cohort of girls the AS04v (2D) would require a 
total annual CCV capacity of 18.5m³ vs. 82.7m³ for the 6/11/16/18V (3D) or 55.2m³ for 
6/11/16/18V (2D). ConClusions: The AS04v was estimated to require between 3.0 
and 4.5 less total CCV than the 6/11/16/18V per vaccinated cohort in Bangladesh. 
This could translate into substantial logistical costs saved in Bangladesh.
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objeCtives: Saudi Arabia is the most important pharmaceutical market in the 
Middle East with a quickly growing population, a GDP in the top 30 globally and a 
high willingness to pay for pharmaceuticals. This represents a very attractive market 
for biopharmaceutical companies and their respective therapies as the market is 
expected to reach nearly $5B USD by 2016. This research aimed to understand the 
evolving and complex reimbursement landscape in the country and develop strate-
gies to capitalize on opportunities in the region, specifically focusing on high cost 
oncology therapeutics. Methods: The research was conducted through in-depth 
interviews with payers and clinicians across each government sector/ministry in 
Riyadh, Jeddah and Dammam. Results: The health care system in Saudi Arabia 
is decentralised and reimbursement decisions are made by individual government 
sectors (ministries). Recent reforms in the health care system have attempted to 
create a movement towards being more cost conscious. The majority of pharmacy 
departments at specialist hospitals in the leading 3 cities conduct pharmacoeconomic 
reviews, with varying rigor, although the impact is much less than that of the clinical 
review. Currently, the Saudi FDA is the regulatory authority in the country for pricing 
and reimbursement; however there is an increasing trend where pharmaceutical 
companies are taking alternate avenues to get high cost products reimbursed in the 
country. We identified and qualified opportunities and threats for high cost oncology 
products in the region. ConClusions: Despite the complexity of the market, invest-
ing in this large and developing marketplace will surely raise the profile of the country 
and provide great opportunity for the manufacturer. Given the large population and 
high willingness to pay, Saudi Arabia represents a very attractive market that should 
not be overlooked by pharmaceutical companies. Navigating the labyrinth strategi-
cally will ultimately help manufacturers achieve formidable success in the market.
PCN242
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CaNCer DrUgS FUND reqUeSTS
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objeCtives: The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable 
cancer patients to gain access to therapies that are not routinely available on the 
NHS. A national CDF cohort policy lists drugs to be funded for patients who meet 
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objeCtives: Ethics committees often require cross-over design for highly sen-
sitive circumstances where it may be unethical to withhold active therapy. This 
can be the case particularly in oncology. Cross over can, however, dilute the treat-
ment effect seen in trial analyses. The German Institute for Quality and Efficiency 
in Health Care (IQWiG) follows distinct thresholds for comparative treatment 
effect, which it requires for a positive early benefit assessment (EBA) rating. The 
upper 95% confidence interval must be at least 0.85 to receive the highest rating. 
We evaluated if cross-over designs may negatively affect benefit assessment in 
Germany. Methods: Oncology medicines that finished EBA procedures in Germany 
until June 2014 were evaluated for cross over in the manufacturer’s dossier. The 
extent of cross over on the observed treatment effects was investigated, as well 
as how the designs may affect the EBA ratings. Results: Ten out of 24 EBAs in 
oncology included assessment of trials with cross-over design. Cross over may have 
affected the observed treatment effects as demonstrated by a number of examples. 
Firstly, the proportion of patient cross over was as high as 62% for crizotinib. For van-
detanib, 12 out of 13 remissions in the control group could be attributed to a switch 
to active therapy. The hazard ratio for overall survival (OS) with vemurafenib versus 
dacarbazine was 0.37 without cross over at first data-cut in comparison to 0.62 with 
24% cross over at a later timepoint. These examples suggest that cross-over designs 
are both present in EBAs in oncology, and may affect the extent of comparative 
treatment effect. The affect of cross-over design was not systematically considered 
by IQWiG. ConClusions: Cross-over design is an ethical necessity. However, it is 
known that these designs dilute treatment effect signals. German HTA EBAs need 
to improve in systematically accounting for such cross-over affects.
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reimbUrSeD PharmaCoTheraPy oF meTaSTaTiC Clear Cell KiDNey 
CaNCer (mCCKC) iN The CzeCh rePUbliC
Mazelova J., Slaby J.
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objeCtives: Concise analysis of reimbursement of drugs for mCCKC. Evaluation 
was performed from the aspect of the regulator; it regards drugs approved for use 
in outpatient care. The aim was to identify the development of criteria that must be 
met by reimbursed drugs, with regard to pharmacoeconomics and evidence-based 
medicine data. Methods: We performed a search of the database of administrative 
proceedings (including proceedings on reimbursement determination as well as on 
reimbursement revisions) and detected those in which the Decision has already 
been made. Subsequently, an analysis of submitted evidence was carried out in 
cases where the reimbursement conditions were first set or amended. Results: 
Between Jan/2008 and Jun/2014, decisions were issued in 25 relevant proceedings 
regarding 9 drugs. Before 2008 (when the pricing and reimbursement decision com-
petence was transferred to the Institute) only interpheron-alpha (IFN) and inter-
leukin-2 (IL2) were reimbursed in this indication. The proceedings carried out by 
the Institute led in IFN and IL2 only to precision of the conditions to better reflect 
real clinical practice (obsolete regimens were left out). In IL2 the reimbursement 
conditions for the 1st line of treatment were extended to include the combination 
with bevacizumab (no pharmacoeconomics required as the evidence had already 
been assessed and relevant conditions approved for bevacizumab). For the other 
medicines, the reimbursement conditions were set or amended based on scientific 
evidence and pharmacoeconomics (1st line: sunitinib ICER/LYG: 25,9 t€ , sorafenib 
ICER/PFLY: 42,8 t€ , bevacizumab: 96,3 t€ ; 1st and 2nd line: pazopanib - CMA analysis 
vs. sunitinib; 2nd line: axitinib ICER/QALY 57,0 t€ , 2nd or 3rd line: everolimus: ICER 
per LYG: 6,9 t€ , ICER; temsirolimus: only costs per LYG: 13,7 t€ ). ConClusions: 
Setting the reimbursement conditions depended not only on the submitted evi-
dence and pharmacoeconomic data but also on other elements (public interest, 
burden of the disease).
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reimbUrSemeNT oF TargeTeD CaNCer TheraPieS WiThiN Three DiFFereNT 
eUroPeaN healTh Care SySTemS
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objeCtives: To identify differences in the recommendations for targeted cancer 
therapies (TCT) in three distinctive European health care systems: Serbian, Scottish 
and Dutch, and to examine the role of cost effectiveness analyses (CEA) in such 
recommendations. Methods: A list of currently approved TCTs cited from the 
European Medicines Agency (EMA) was cross-referenced with the drug reimburse-
ment reports issued by Health Insurance Fund (RFZO) for Serbia, Scottish Medicines 
Consortium (SMC) for Scotland and Health Institute (ZI) for the Netherlands. The 
following key variables were gathered from the reports: drug indication, registra-
tion status, reimbursement status and outcome of the cost effectiveness evalu-
ation. Results: There were 44 TCTs indicated for 75 cancer sites and approved 
by EMA. Out of total number of drugs per indication (d/i= 75), 20 were reimbursed 
in Serbia, and 15 are still without the decision from RFZO. Remaining majority of 
TCTs is not registered in Serbia. None of submissions neither CEAs were publically 
available. SMC positively assessed 25 d/i and rejected as much as 30. All apprais-
als were published, and majority contained full CEAs. Finally, Dutch ZI accepted 
total of 59 d/i and disapproved use of only 5 d/i. The majority of reimbursed drugs 
were exempted from CEA in accordance with the policy for expensive hospital 
drugs. ConClusions: Although data collected for Serbia did not allow us to evalu-
ate practiced policy in broader extent, it is certainly surrounding with the smallest 
number of reimbursed TCTs. Surprisingly, TCTs in Scotland were comparable to 
this number, yet reasons for such an outcome were fairly different. It seems that 
full application of CEA in TCTs submission contributed to 55% of SMC negative 
Cancer Institute, Bratislava, Slovak Republic, 4Easter-Slovakian Cancer Institute, Košice, Slovak 
Republic, 5Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic, 6Amgen Bulgaria EOOD, 
Sofia, Bulgaria
objeCtives: FN is a cost-intensive complication of chemotherapy. The study aimed to 
describe HCRU in hospitalized FN patients in BG, CZ and SK. Methods: Multicentre 
international, retrospective, observational study in adult patients, who received the 
chemotherapy leading to the first (= index) FN event between 01/2009 and 09/2012. 
FN-specific HCRU parameters included infection prophylaxis and treatments, G-CSF 
use, other prophylactic medication, specific interventions and investigations, and 
FN-related hospitalizations. Unless otherwise stated, country data are reported in 
the order BG–CZ–SK. Results: 314 patients (156, 79, 79) with a median age of 55.5, 
56.0, and 57.0 years, and mostly ECOG status 0-2 (81%, 100%, 91%) were analysed. Most 
frequent STs and HMs were breast cancer (23% BG; 24% SK), testicular cancer (28% CZ); 
acute myeloid leukemia (29% BG), non-follicular lymphoma (31% CZ; 33% SK). G-CSF 
was used in the index cycle by 92%, 91%, and 68% of patients, usually as treatment 
(64%, 27%, 57%) rather than primary prophylaxis (20%, 41%, 8%). Most patients had one 
FN episode (88%, 96%, 94%), mostly in cycle 1 (56%; 72%; 58%). The mean (SD) number 
of FN-related hospital days was 7.2 (4.78), 7.2 (6.04), and 9.2 (5.12), with generally 
longer stays in HM than ST patients. The number of FN-related investigations in the 
index cycle were 531 in 125 patients (80%), 496 (49; 62%), and 585 (66; 84%); FN-related 
interventions: 416 (109; 70%), 328 (46; 58%), and 473 (55; 70%), respectively. The most 
frequent investigations were blood tests; the most frequent interventions were IV 
fluids and blood transfusions. Anti-infectives were frequently administered in the 
index cycle (72%, 98%, 99%). G-CSF use, FN-related investigations, interventions and 
anti-infective use continued in subsequent cycles. ConClusions: Results indicate 
considerable HCRU in patients experiencing FN in all countries. Frequent lack of G-CSF 
primary prophylaxis was observed, particularly in SK.
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aWareNeSS oF breaST CaNCer aND iTS PreveNTioN. a ComParaTive 
SUrvey amoNg FiNNiSh aND hUNgariaN WomeN
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bACkgRound: Finland has more favourable profile in breast cancer statistics 
compared to Hungary, along with an almost double participation rate in screening 
examinations. However, regarding medical practice and access to latest treatment 
only minor differences exist. Main hypothesis of the research was that awareness, 
knowledge and therefore better attitude towards breast cancer screening explains 
the difference in primary prevention’s efficiency. objeCtives: The aim of the ques-
tionnaire survey was to assess what extent women are aware of the prevention 
opportunities in their home country as well as being aware of risk factors of breast 
cancer; furthermore what impact does it have on their behaviour how they assess 
their own general health status and risk of cancer. Methods: A web-based ques-
tionnaire survey was carried out in 2013-2014 among adult women. Demographic 
characteristics, lifestyle, general and cancer-specific health status (including per-
sonal and family history of breast cancer), knowledge and experience with primary 
prevention were covered. An internationally utilized medical risk calculator was 
included in the questionnaire for classifying responders based on their calculated 
risk of breast cancer, as well as to compare those to the risk assumed by them-
selves. Results: More than 400 participants were involved in the survey from the 
two countries. There were no significant differences identified in the acknowledged 
personal and family health background. Main difference was in the participation 
inclination in screening. Source of getting information means a major impact on 
prevention-related behaviour. Formal education and informing by medical staff 
were the most effective, however magnitude of uncontrolled ‘self-education’ via 
internet and social media is increasing with a potential biasing impact on knowl-
edge. ConClusions: Survey results suggest that utilizing participation ratio in 
comparative screening assessment as a key parameter. Results indicate that partici-
pation can be influenced by increasing efficiency of information flow, with proper 
education as one of the main intervention opportunities.
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likely impact of Net Price referencing on european markets Patel P1, Ladrón de 
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objeCtives: With the introduction of new pricing measures in countries such as 
Germany, the visibility of net pharmaceutical product prices (prices with a manda-
tory rebate) could soon become a requirement. Three European markets that cur-
rently employ rebates are Germany, Spain and Italy. The objective of this study is 
to map out likely consequences of International Price Referencing (IRP) using net 
prices on three products; Avastin, Caprelsa and Vidaza. Methods: Using data from 
PRICENTRIC, we collected net and list ex-factory prices for Avastin, Caprelsa and 
Vidaza across EU-28. Countries that do not use formal IRP as a price setting mecha-
nism were excluded from the analysis, countries that consider price reviews were 
included. Projected prices were calculated using country IRP rules and exchange 
rates from the European Central Bank. The current approved prices were compared 
to the likely projected prices. The analysis investigated two key areas: 1. Countries 
impacted 2. Potential price impact. Results: Figure 1 shows the current prices for 
the 3 products. Figure 2 illustrates the countries impacted by the change and likely 
price points. One of the first countries affected would be Netherlands (Netherlands 
reviews prices every 6 months), followed closely by Switzerland and Ireland. The 
potential impact could range from price reductions of 9.69% for Vidaza in Ireland to 
30.77% for Avastin in Switzerland. ConClusions: The trend for net price referenc-
ing has already been adopted by Greece since February 2014 where Greece moved 
from referencing the Italian list price to the net price. The concern for industry if 
this were to become the norm for other markets and if net prices were to become 
publically visible, substantial price reductions could be on the horizon.
